

# Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538  
17 March 2020 16:30:00 CET - Lund, Sweden



## NeuroVive Pharmaceutical AB (publ): report from EGM

**Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed with the required majority.**

### **Approval of resolution to issue shares with preferential rights for existing shareholders**

The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution on 19 February 2020 to increase the company's share capital by not more than SEK 4,648,814.75 by a rights issue of not more than 92,976,295 shares with preferential rights for existing shareholders.

The right to subscribe for shares in the rights issue shall apply to persons whom on the record date for the rights issue are registered as shareholders in the company. One (1) existing share entitles to one (1) subscription right and two (2) subscription rights entitles to subscription of one (1) new share. The record date for determining which shareholders whom are entitled to subscribe for shares with preferential right shall be Wednesday 1 April 2020. Subscription of shares with subscription rights shall be made through payment in cash during the period from and including 6 April 2020 up to and including 24 April 2020. The Board of Directors shall have the right to extend the subscription and payment period. Notification of interest to subscribe for shares without subscription rights is possible during the subscription period. The subscription price per share is SEK 0.80.

Upon full subscription of the rights issue, the Company will raise approximately SEK 74 million before issuance costs.

### **Contacts**

---

Catharina Johansson, CFO, IR & Communications  
+46 (0)46-275 62 21, [ir@neurovive.com](mailto:ir@neurovive.com)

### **NeuroVive Pharmaceutical AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

[info@neurovive.com](mailto:info@neurovive.com), [www.neurovive.com](http://www.neurovive.com)

For news subscription, please visit <http://www.neurovive.com/press-releases/subscription-page/>

Follow us on [LinkedIn](#)

Subscribe to our [YouTube channel](#)

# Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538  
17 March 2020 16:30:00 CET - Lund, Sweden

---



## About Us

---

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market's Pink Open market in the US (OTC: NEVPF).

## Attachments

---

[NeuroVive Pharmaceutical AB \(publ\): report from EGM](#)